Quick Answer
Cellectar Biosciences, Inc. reported Net Income Loss of -$21.79 million for the year ending 2025.
- Cellectar Biosciences, Inc. showed an increase of +51.1% in Net Income Loss from 2024 to 2025.
- This data is from Cellectar Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2004 to 2025 (22 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 22 years of available data (2004 to 2025), Cellectar Biosciences, Inc.'s Net Income Loss has declined by 6,257.5%.
- Historical annual values: Fiscal year 2025: -$21.79 million | Fiscal year 2024: -$44.58 million | Fiscal year 2023: -$42.77 million | Fiscal year 2022: -$28.60 million | Fiscal year 2021: -$24.12 million | Fiscal year 2020: -$15.09 million | Fiscal year 2019: -$14.09 million | Fiscal year 2018: -$13.24 million | Fiscal year 2017: -$13.56 million | Fiscal year 2016: -$6.18 million | Fiscal year 2015: -$5.50 million | Fiscal year 2014: -$8.05 million | Fiscal year 2013: -$10.78 million | Fiscal year 2012: -$8.80 million | Fiscal year 2011: -$7.44 million | Fiscal year 2010: -$4.56 million | Fiscal year 2009: -$6.22 million | Fiscal year 2008: -$6.09 million | Fiscal year 2007: -$5.09 million | Fiscal year 2006: -$963.4 thousand | Fiscal year 2005: -$481.8 thousand | Fiscal year 2004: -$342.8 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: